Clinical, biological, metabolic and immune changes associated with the use of Sodium-glucose cotransporter 2 inhibitors in people living with HIV
Résumé
Results: Most of the 20 patients with SGLT2i treatment were male (75%), with a median
[IQR] age of 59 [55;68] years, receiving antiretroviral therapy for a median of 21.5 [15.3;26.5] years. Most had type 2 diabetes (95%), chronic kidney disease (90%), dyslipidemia (80%), and hypertension (75%). SGLT2i treatment was associated with a median of 3 kg weight loss, an increase in hematocrit and decreased AST levels. LDL, HDL, oxLDL and Lp-PLA2 levels were unaffected. SGLT2i was associated with inflammasome inhibition, with decreased circulating levels of IL-1β and IL-8. There was also a decrease in cytokines associated with the recruitment and activation of monocytes-macrophages MCP-1, MIP-1α, MIP-1β, Eotaxin, RANTES, IL-8, and their positive feedback, IL-13/IL-4. Decreased IL-6, CRP and sCD14 levels were non-significant. Conclusion : on PWH, SGLT2i was associated with weight loss and a broad impact on innate immunity, with inhibition of inflammasome and monocyte-macrophage activation.
Origine | Fichiers produits par l'(les) auteur(s) |
---|